Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.
1. An Endoglycosidase-S mutant comprising SEQ ID NO: 2 having a D233Q substitution.
2. A method of producing nonfucosylated IgG glycoforms, comprising:
a) deglycosylating an Fc domain of IgG glycoforms to produce a GlcNAc-acceptor;
b) removing α-1,6-fucose moieties by exposing the GlcNAC-acceptor to a concentration of α-fucosidase for an amount of time necessary to defucosylate the GlcNAC-acceptor to yield nonfucosylated GlcNAC-acceptors;
c) enzymatically reacting the nonfucosylated GlcNAc-acceptors with an activated oligosaccharide donor using a Streptococcus pyogenes Endoglycosidase-S Asp233 mutant comprising SEQ ID NO: 2 having a D233Q substitution, wherein the activated oligosaccharide donor carries an oligosaccharide moiety comprising a predetermined number and type of sugar residues.
3. The method of claim 2 , wherein the IgG glycoforms are deglycosylated using an endoglycosidase selected from the group consisting of Endo-H, Endo-F3, wild-type Endo S, and Endo-A.
4. The method of claim 2 , wherein the activated oligosaccharide donor is a synthetic oligosaccharide oxazoline or sialylated oxazoline.
5. The method of claim 4 , wherein the synthetic oligosaccharide oxazoline is a di-, tri-, tetra-, penta-, hexyl-, hepta-, octyl-, nona-, deca- or undeca-saccharide oxazoline.
6. The method of claim 2 , wherein the activated oligosaccharide donor further comprises an additional biologically active agent or a tag.
7. The method of claim 2 , wherein the nonfucosylated IgG glycoform is a monoclonal antibody selected from the group consisting of 17b, 48d, A32, C11, 2G12, F240, IgG1b12, 19e, X5, TNX-355, cetuximab, rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, I-131 tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, IGN101, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, CAT-3888, CDP-791, eraptuzumab, MDX-010, MDX-060, MDX-070, matuzumab, CP-675,206, CAL, SGN-30, zanolimumab, adecatumumab, oregovomab, nimotuzumab, ABT-874, denosumab, AM 108, AMG 714, fontolizumab, daclizumab, golimumab, CNTO 1275, ocrelizumab, HuMax-CD20, belimumab, epratuzumab, MLN1202, visilizumab, tocilizumab, ocrerlizumab, certolizumab pegol, eculizumab, pexelizumab, abciximab, ranibizimumab, mepolizumab and MYO-029.
8. The method of claim 2 , wherein the nonfucosylated IgG glycoforms are substantially homogeneous.